| National trends in use of sodium‐glucose cotransporter‐2 inhibitors and glucagon‐like peptide‐1 receptor agonists by cardiologists and other specialties, 2015 to 2020 R Adhikari, K Jha, Z Dardari, J Heyward, RS Blumenthal, RH Eckel, ... Journal of the American Heart Association 11 (9), e023811, 2022 | 86 | 2022 |
| Online searches for SGLT-2 inhibitors and GLP-1 receptor agonists correlate with prescription rates in the United States: an infodemiological study O Dzaye, P Berning, AC Razavi, R Adhikari, K Jha, K Nasir, JW Ayers, ... Frontiers in cardiovascular medicine 9, 936651, 2022 | 15 | 2022 |
| LP (a): structure, genetics, associated cardiovascular risk, and emerging therapeutics E Tasdighi, R Adhikari, O Almaadawy, TM Leucker, MJ Blaha Annual Review of Pharmacology and Toxicology 64 (1), 135-157, 2024 | 13 | 2024 |
| New insights into prescribing of SGLT2 inhibitors and GLP-1 receptor agonists by cardiologists in 2020: major barriers limiting role R Adhikari, M Blaha Am Coll Cardiol, 2021 | 13 | 2021 |
| Transitioning to GLP-1 RAs and SGLT2 inhibitors as the first choice for managing cardiometabolic risk in type 2 diabetes KK Jha, R Adhikari, E Tasdighi, N Osuji, T Rajan, MJ Blaha Current atherosclerosis reports 24 (12), 925-937, 2022 | 9 | 2022 |
| Cardiovascular risk stratification among individuals with obesity: The Coronary Artery Calcium Consortium E Boakye, GR Grandhi, Z Dardari, R Adhikari, G Soroosh, K Jha, O Dzaye, ... Obesity 31 (9), 2240-2248, 2023 | 5 | 2023 |
| Vascular control of kidney epithelial transporters MA Sparks, E Dilmen, DL Ralph, F Rianto, TA Hoang, A Hollis, EJ Diaz, ... American Journal of Physiology-Renal Physiology 320 (6), F1080-F1092, 2021 | 5 | 2021 |
| Cardiologist use of SGLT2 inhibitors and GLP-1 receptor agonists since release of favorable cardiovascular outcomes trials: a national study R Adhikari, J Heyward, GC Alexander, M Blaha Journal of the American College of Cardiology 77 (18_Supplement_1), 1468-1468, 2021 | 5 | 2021 |
| Unmet role of cardiologists: use of cardiometabolic drugs that lower cardiovascular risk R Adhikari, T Rajan, M Blaha American College of Cardiology. Available at: https://www. acc. org/latest …, 2020 | 4 | 2020 |
| Comparing prescription trends for oral and subcutaneous glucagon-like peptide-1 receptor agonists (GLP-1 RA) in the United States R Adhikari, G Grandhi, MJ Blaha Journal of the American College of Cardiology 81 (8_Supplement), 1868-1868, 2023 | 3 | 2023 |
| Unmet role of cardiologists: use of cardiometabolic drugs that lower cardiovascular risk. American College of Cardiology R Adhikari, T Rajan, M Blaha | 3 | 2021 |
| Coronary artery calcium in 2023: Guidelines for LDL-C goals, non-statin therapies, and aspirin use GP Soroosh, E Tasdighi, R Adhikari, MJ Blaha Progress in Cardiovascular Diseases, 2024 | 1 | 2024 |
| Online searches for hepatocellular carcinoma drugs mirror prescription trends across specialties and changes in guideline recommendations P Berning, AE Schroer, R Adhikari, AC Razavi, FH Cornelis, JP Erinjeri, ... Frontiers in Oncology 14, 1324095, 2024 | 1 | 2024 |
| Nephrologist Use of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors Relative to Other Specialties, 2015-2022: FR-PO902 R Adhikari, K Jha, MJ Blaha Journal of the American Society of Nephrology 33 (11S), 572, 2022 | 1 | 2022 |
| Longitudinal Analysis of Obesity Drug Use and Public Awareness P Berning, R Adhikari, AE Schroer, YA Jelwan, AC Razavi, MJ Blaha, ... JAMA Network Open 8 (1), e2457232-e2457232, 2025 | | 2025 |
| THE UNTAPPED POTENTIAL OF COLCHICINE IN CARDIOVASCULAR PREVENTION O Mhaimeed, M Khorsandi, R Adhikari, MJ Blaha Journal of the American College of Cardiology 83 (13_Supplement), 1826-1826, 2024 | | 2024 |
| USE OF SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS BY CARDIOLOGISTS SINCE THE RELEASE OF 2022 AHA/ACC/HFSA GUIDELINES FOR THE MANAGEMENT OF HEART FAILURE GR Grandhi, R Adhikari, E Tasdighi, AD Osei, M Khorsandi, A Mehta, ... American Journal of Preventive Cardiology 15, 100572, 2023 | | 2023 |
| Use of Colchicine Since FDA Approval of LoDoCo for ASCVD Prevention O Mhaimeed, M Khorsandi, R Adhikari, MJ Blaha | | 2023 |
| Abstract P514: Evaluating the Concordance Between Trends in Prescription Volume and Online Interest for the Weight Loss Formulation of Semaglutide R Adhikari, O Dzaye, MJ Blaha Circulation 147 (Suppl_1), AP514-AP514, 2023 | | 2023 |
| Abstract P269: Sodium Transporter Profile in Mice Lacking AT1A Receptors in the Renal Proximal Tubule AA McDonough, AK Izuhara, Z Xiang, DL Ralph, R Adhikari, SB Gurley Hypertension 68 (suppl_1), AP269-AP269, 2016 | | 2016 |
Michael J. Blaha MD MPHProfessor of Cardiology & Epidemiology, Director Clinical Research, Johns Hopkins Ciccarone CenterEmail verificata su jhmi.edu